George S. Eisenbarth: Insulin and Type 1 Diabetes
نویسندگان
چکیده
منابع مشابه
George S. Eisenbarth: Insulin and Type 1 Diabetes
G eorge S. Eisenbarth, MD, PhD, could be considered a natural conduit in the research of type 1 diabetes (T1D) and the fields of endocrinology and immunology. His recognition of T1D as a chronic autoimmune disease has advanced the field toward prediction, prevention, and clinical trials. His focus on insulin as the key autoantigen in islet autoimmunity unraveled the molecular basis of the insul...
متن کاملInsulin treatment and type 1 diabetes topics.
Insulin treatment Basal insulin. Malcolm Nattrass (Birmingham, U.K.) discussed basal insulin analogs, noting that the ideal approach will lead to “a flat profile that is reproducible.” The development of basal insulin began with protamine zinc insulin in 1936, followed by NPH insulin in 1946 and zinc insulins lente, semilente, and ultralente in 1951. All of these preparations have high variabil...
متن کاملInsulin Sensitizers for Type 1 and Type 2 Diabetes
A number of fascinating reports discussed treatment with metformin. Jones and colleagues studied 82 children with type 2 diabetes aged 10 to 16 years who had an average HbA1c of 8.6%, fasting glucose of 182 mg/dL, and weighing 92 kg. Results of this study showed that metformin at a dose of 500-1000 mg twice daily lowered fasting glucose levels by 43 mg/dL in 40 patients. Patients in the control...
متن کاملInsulin therapy in type 1 diabetes.
Although not curable, type 1 diabetes is eminently controllable. IIT, as guided by the results of landmark studies such as the DCCT, provides primary care providers with a blueprint for reducing the frequency of the devastating complications of diabetes that were all too common in the recent past. Considering the remarkable advances in contemporary therapy, including MDI and CSII, the likelihoo...
متن کاملInsulin Degludec in Type 1 Diabetes
OBJECTIVE Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes. RESEARCH DESIGN AND METHODS In this 16-week, randomized, open-label trial, part...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Care
سال: 2013
ISSN: 0149-5992,1935-5548
DOI: 10.2337/dc13-0753